Company: PACB
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001299130-25-000168
Chunk: 6

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
 comprehensive income415 422 Accumulated deficit (2,654,931)(2,148,926)Total stockholders’ equity 36,090 506,594 Total liabilities and stockholders’ equity $803,158 $1,260,447 

See accompanying notes to the condensed consolidated financial statements.

Q3 Fiscal 2025 Form 10-Q3

Table of Contents

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited)

Three Months Ended September 30,Nine Months Ended September 30,(In thousands, except per share amounts)2025202420252024Revenue:Product revenue $32,597 $35,296 $96,793 $102,051 Service and other revenue 5,844 4,671 18,567 12,739 Total revenue 38,441 39,967 115,360 114,790 Cost of Revenue:Cost of product revenue 19,204 23,278 65,559 68,808 Cost of service and other revenue 3,078 3,484 11,709 10,588 Amortization of acquired intangible assets183 3,201 4,711 7,172 Loss on purchase commitment75 — 4,167 998 Total cost of revenue 22,540 29,963 86,146 87,566 Gross profit15,901 10,004 29,214 27,224 Operating Expense:Research and development 22,846 25,516 74,428 107,456 Sales, general and administrative 31,099 43,746 107,442 133,376 Impairment charges— — 15,000 93,200 Amortization of acquired intangible assets833 3,649 363,708 13,377 Change in fair value of contingent consideration— 1,170 (18,700)1,100 Total operating expense 54,778 74,081 541,878 348,509 Operating loss (38,877)(64,077)(512,664)(321,285)Interest expense (1,739)(3,538)(5,214)(10,655)Other income, net 2,999 6,890 11